Shay Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Shay Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,000	Closed	-$351K	–	489
2020 Q4	$351K	Buy	+4,000	New	+$317K	0.08%	187

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Shay Capital's BMRN Position: Q1 2021 in Review

Shay Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 4,000 shares — an estimated $351K sold.

Shay Capital first reported a position in BMRN in Q4 2020 and held it in 1 quarter. The position peaked at $351K in Q4 2020. 530 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

Shay Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Shay Capital sold 4,000 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $351K.
Shay Capital first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Shay Capital's BioMarin Pharmaceuticals position peaked at $351K in Q4 2020.
530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Shay Capital's 13F filing for Q1 2021, filed 13 Aug 2021.